Tetany News and Research

RSS

Examining hypomagnesemia in critically ill patients with Acute Kidney Injury (AKI)

In this interview, News-Medical talks to Dr. Francesca Di Mario, about hypomagnesemia in critically ill patients suffering from acute kidney injuries and discusses how Nova Biomedical instruments are utilized in her work.

From Nova Biomedical 6 Apr 2022

EDMA to endorse the campaign on Hypoparathyroidism

On the occasion of the World Hypoparathyroidism Awareness Day 2011, EDMA, the European Diagnostic Manufacturers Association, highlights the crucial role the In Vitro Diagnostic (IVD) industry can play to effectively testing this rare endocrine condition.

5 Jan 2011

ViroPharma announces data on safety, efficacy of Cinryze to treat acute angioedema attacks

ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.

6 Aug 2010

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today its support for the second annual U.S. Rare Disease Day observance on February 28.

1 Mar 2010